The CD109 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population featuring targeted disruption of the CD109 gene in the A-549 human lung adenocarcinoma epithelial cell line. This product provides a heterogeneous pool of edited cells suitable for immediate functional studies without clonal isolation, enabling robust analysis of CD109-mediated regulation.
The A-549 cell line is a widely utilized model in cancer biology and drug testing, derived from human lung adenocarcinoma. Its epithelial origin and intact TGF-?? signaling machinery make it an ideal host for investigating the consequences of CD109 loss in a physiologically relevant tumor context. A-549 cells are commonly employed to study signaling pathways, proliferation, and metastasis.
CD109 is a GPI-anchored glycoprotein that negatively regulates TGF-?? signaling by binding to TGF-?? receptors (T??RI and T??RII) and promoting their internalization and degradation via caveolae-mediated endocytosis, a process involving interactions with caveolin-1, Smad7, and E3 ubiquitin ligases. This attenuates phosphorylation of Smad2/3 and downstream transcriptional responses. CD109 expression is induced by TGF-??1, TGF-??2, EGF, hypoxia, and STAT3, and its activity further modulates AKT and ERK1/2 phosphorylation, MMP expression, and EMT markers. Thus, CD109 integrates signals from TGF-??/Smad, JAK/STAT, PI3K/AKT, and MAPK/ERK pathways.
In A-549 lung adenocarcinoma cells, CD109 knockout serves as a critical tool to dissect TGF-?? pathway dynamics, particularly in the context of tumor progression where TGF-?? switches from tumor-suppressive to pro-metastatic. The polyclonal knockout population allows examination of enhanced TGF-?? signaling on proliferation, migration, invasion, and EMT, and facilitates investigation of CD109 as a potential therapeutic target in non-small cell lung cancer and other malignancies.
Key applications include Western blotting for Smad2/3 phosphorylation, TGF-??-responsive luciferase reporter assays, RT-qPCR of target genes, immunofluorescence for receptor localization, co-immunoprecipitation of CD109 with T??RI/T??RII, and functional migration/invasion assays. Flow cytometry can assess CD109 surface expression. These cells support drug resistance studies, functional genomics screens, and target validation. For technical inquiries, contact Ascent Research.
